Business context and reporting period
This is Synaptogenix, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022 (filed May 13, 2022), not a filing identified in the request metadata as TAO Synergies Inc. Synaptogenix is a clinical-stage biopharmaceutical company developing Bryostatin-1, primarily for Alzheimer’s disease, and exploring other indications. It reported no product revenue.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $1.49 million | $1.15 million; up 29.0% |
| General and administrative | $1.80 million | $2.00 million; down 10.3% |
| Total operating expenses | $3.28 million | $3.16 million; up 3.9% |
| Net loss | $3.28 million | $3.15 million; loss increased 3.9% |
| Basic and diluted loss per share | $0.47 | $1.06 |
| Operating cash used | $3.49 million | $3.59 million |
| Cash and cash equivalents | $31.28 million at March 31 | $34.21 million at December 31, 2021 |
No gross margin is applicable given the absence of revenue. The balance sheet reports no debt; current liabilities were $669,338, against current assets of $32.33 million. Working capital was $31.66 million. Cash declined by $2.93 million in the quarter; $553,150 came from warrant exercises, with no new private-placement proceeds.
Material changes and unusual items
R&D increased mainly with spending on the Alzheimer’s Phase 2 study. G&A declined, including lower legal, consulting, and compensation-related costs, partly offset by higher noncash stock compensation and insurance expense. Stock-based compensation was $711,558, versus $568,239 a year earlier. The company issued shares and warrants for consulting services and received approximately $553,000 from warrant exercises. The NIH grant’s full $2.7 million was substantially received; approximately $100,000 reduced R&D expense in the quarter.
Outlook, risks, and contingencies
Management expected approximately $30.5 million of cash at the filing date to fund projected operating requirements for at least 12 months from filing, including the current Bryostatin-1 development plan. It expects the current Alzheimer’s Phase 2 trial to be materially concluded by year-end 2022 and R&D spending to level off, although other development costs could rise. The WCT study budget was revised to approximately $12.0 million, with an estimated net company cost of $9.3 million after NIH funding; cumulative trial expenses were approximately $8.2 million at quarter-end.
The filing describes a prior confirmatory Phase 2 Alzheimer’s study that did not meet statistical significance on its primary endpoint. The company cited a post-hoc moderate-stratum signal, but the treatment-placebo difference was not statistically significant. Management also described plans for a Fragile X trial with Nemours, estimated at approximately $700,000, and a Cleveland Clinic collaboration on possible multiple-sclerosis studies; future work and costs for the latter were not specified.
Risks include the uncertain efficacy and regulatory path for drug candidates, trial enrollment or pandemic-related delays, dependence on adequate bryostatin supply, and the need for future capital to pursue additional projects. The company cautioned that future equity financing could be dilutive and debt could carry restrictive terms. It reported approximately $27.5 million invested in a money market fund not insured by the FDIC and approximately $3.8 million in cash balances above FDIC-insured amounts. It also disclosed uncapped separation-related indemnification obligations, though no related claims or indemnification liabilities were reported. No legal proceedings or subsequent events were reported.
Investor verification points
- Confirm the issuer: the supplied filing is for Synaptogenix, Inc. (Nasdaq: SNPX), not TAO Synergies Inc.
- Review the Phase 2 trial’s status, results, enrollment, and remaining costs, and distinguish prespecified findings from post-hoc analyses.
- Assess the stated 12-month cash runway against ongoing trial spending and the need for capital to fund further development.
- Check the availability and sufficiency of bryostatin supply and the costs and status of proposed additional indication studies.
- Review the disclosed ineffective disclosure controls, including weaknesses in segregation of duties, financial reporting processes, and IT controls.
- Reconcile reported weighted-average shares of 6,939,200 for Q1 2022 with the reported March 31 outstanding share count of 6,809,647, and verify per-share data.